Evaluation of donor hepatic iron concentration as a factor of early fibrotic progression after liver transplantation

J Hepatol. 2004 Aug;41(2):307-11. doi: 10.1016/j.jhep.2004.04.021.

Abstract

Background/aims: Hepatic iron may act as an important co-morbid factor in non-hemochromatotic liver diseases, but whether it may favour fibrogenesis after liver transplantation is not known. To verify whether the hepatic iron concentration of the graft might play a role in the rapid fibrotic progression frequently observed after liver transplantation for chronic hepatitis C.

Methods: The hepatic iron concentration, measured at the time of the donor operation, was retrospectively related to the histological follow-up data of 68 recipients (49 males, 19 females), of whom 38 were hepatitis C virus positive.

Results: The hepatic iron concentration in donor liver biopsies ranged from 25 to 7,100 microg/gdw. After a median follow-up of 19 months, nine patients (five HCV positive) had a staging score >3. There was a significant association between a higher frequency of increasing staging and donor age >50 years. In female HCV-positive recipients, a graft hepatic iron concentration >1,200 microg/gdw was associated with fibrosis progression >0.15 fibrosis units per month (4/4 vs. 1/7, p<0.01).

Conclusions: The graft hepatic iron concentration may be one of the factors involved in early fibrosis progression due to recurrent hepatitis C in female recipients.

MeSH terms

  • Adult
  • Aged
  • Biopsy
  • Disease Progression
  • Female
  • Follow-Up Studies
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / surgery*
  • Humans
  • Iron / metabolism*
  • Liver / metabolism*
  • Liver / pathology
  • Liver Cirrhosis / etiology
  • Liver Cirrhosis / metabolism*
  • Liver Cirrhosis / pathology*
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Osmolar Concentration
  • Postoperative Period
  • Recurrence
  • Sex Characteristics
  • Tissue Donors*

Substances

  • Iron